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Under appropriate conditions tight, noncovalent binding of 2-azido-adenine ucleotides toeither catalytic 
or noncatalytic binding sites on the E. coli Fr-ATPase. occurs. After removal of unbound ligands, UV-irradi- 
ation results primarily in the covalent incorporation of nucleotide moieties into the B-subunit n both cata- 
lytic and noncatalytic site labeling experiments. Minor labeling of the cc-subunit was also observed. After 
trypsin digestion and purification of the labeled peptides, microsequencing studies identified two adjacent 
B-subunit tryptic peptides labeled by 2-azido-ADP or -ATP. These /&subunit peptides were labeled on tyro- 
sine-331 (catalytic sites) and tyrosine-354 (noncatalytic sites) in homology with the labeling patterns of the 
mltochondrial nd chloroplast enzymes. 
H+-ATPase; Oxidative phosphorylation; Photoaffinity analog; Azido-ATP; (E. co/i) 
1. INTRODUCTION 
E. coli membranes contain an ATP synthase 
(FIFO type) from which an ATPase (EFi) is readily 
purified that is similar to the ATPases derived 
from mitochondria (MFr) and chloroplasts (CFr) 
[l-4]. The E. coli ATP synthase is an oligomeric 
enzyme composed of eight nonidentical subunits 
arranged in two sectors, Fi and Fo. FO is comprised 
of three integral membrane proteins of complex 
stoichiometry and is known to facilitate proton 
transport through the membrane. E. coli Fr is com- 
posed of five proteins in the stoichiometry a&y&, 
is peripheral to the membrane, and contains the 
sites of ATP hydrolysis and synthesis. 
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EFi, like MFi, contains six total nucleotide 
binding sites, three of which are potential catalytic 
sites, and three that are referred to as noncatalytic 
sites [5,6]. Noncatalytic sites are relatively specific 
for adenine nucleotides and do not participate 
directly in catalysis. Isolated EFr a-subunit con- 
tains a nucleotide binding site that is similar in 
properties to the noncatalytic binding sites of Fi 
[7,8]. Catalytic sites on MFI and EFi can be 
induced to exchange readily bound nucleotide with 
medium nucleotide, while nucleotides bound at 
noncatalytic sites exchange with medium 
nucleotides very slowly with or without catalytic 
turnover [5,6]. Using the photoactivatable ATP 
analog, 2-azido-ATP, and conditions that allow 
the binding of nucleotide to either catalytic or non- 
catalytic binding sites, we have been able to modify 
specifically and covalently both classes of binding 
sites in EFi. We report the results of the modifica- 
tion and sequencing of two adjacent P-subunit 
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tryptic peptides corresponding to the catalytic and 
noncatalytic nucleotide binding sites. We briefly 
summarize the results of similar studies performed 
on MFr and CFr ATPases. 
2. EXPERIMENTAL 
EFr was prepared from E. coli K12 strain 
AN1460 [lo] by the procedures described in 
[ 11,121. Cells were grown in 150 1 fermenters on 
either LB or supplemented minimal media. Syn- 
thesis of 2-azido-ATP was as described in [13,14]. 
Differential labeling of catalytic or noncatalytic 
binding sites was performed essentially as de- 
scribed in [ 151 except that 2-azido-ATP was 
substituted for imido-ATP. The incubation buffer 
used in each experiment contained Mg2+ (50 mM 
Tris-Sod, 0.5 mM EDTA, 2.5 mM MgC12, pH 
8.0). 3 ml Sephadex-centrifuge columns [16] equil- 
ibrated in the incubation buffer were used 
throughout. Irradiation, acid precipitation, and 
proteolysis of Fi samples were performed essential- 
ly as described in [14]. Succinylation of Fr when 
performed followed the procedures in [ 171. 
Routine procedures were as described in [15]. Se- 
quencing of purified peptides was performed by 
the automated Edman degradation method on an 
Applied Biosystems M470. Amino acid composi- 
tions were determined by the Waters Pica-Tag 
system. All of the sequences and compositions 
reported in this study have been reproduced. 
Purification of peptides for sequencing took ad- 
vantage of the anionic character of peptides 
modified with ADP or ATP (ANP) moieties by 
first employing anion-exchange HPLC. Nonsuc- 
cinylated tryptic peptides from EFr samples la- 
beled with 2-azido-ATP were directly injected into 
a Waters/Millipore HPLC system employing a 
Whatman Partisil PXS25/SAXlO ion-exchange 
column (4.6 x 250 mm). After a 5 min isocratic 
elution, the labeled peptides were eluted by a 
50 min gradient from 100% solvent A (29: 71, 
acetonitrile:O.Ol M NaH2P04, pH 4.0) to 100% 
solvent B (29:71, acetonitrile:0.4 M NaH2P04, 
pH 3.0). Absorbance was followed at 215 and 
260 nm. Fractions (collected manually) were 
analyzed for radioactivity by Cerenkov counting. 
32P-containing peaks with high 260/215 nm absor- 
bance ratios were individually lyophilized and 
separated by HPLC on a Vydac CS reversed-phase 
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column. Gradient elution from 0.1 ~01% 
trifluoroacetic acid to 0.1% trifluoroacetic acid, 
90 ~01% acetonitrile resulted in purification of the 
labeled peptides. Estimations of recoveries were 
based on the specific radioactivity of the 32P- 
azidonucleotide used. 
3. RESULTS 
3.1. Differential labeling of catalytic or 
noncatalytic binding sites by 2-azido-A TP 
Fig.1 shows an HPLC elution profile of tryptic 
peptides of EFr photolabeled by 2-azido-ANP 
bound at catalytic sites, separated only by a single 
Cd reversed-phase column. Briefly, ammonium 
sulfate-precipitated EFr (5 mg) was redissolved in 
0.4 ml of incubation buffer and desalted by a 
Sephadex-centrifuge column. Noncatalytic sites 
were first filled with nonradioactive nucleotide 
(1 mM ATP, 30 min). Removal of free ATP, ADP 
and Pi by a Sephadex-centrifuge column was 
followed by incubation in the dark with 2-azido- 
p,y-32P]ATP (0.75 mM, 15 min) to allow the ex- 
change of medium 2-azido-ATP with Fr-bound 
ANP present at catalytic sites. Following a final 
Sephadex-centrifuge column, the sample was ir- 
radiated for 30 min, acid-precipitated, suc- 
cinylated and digested with trypsin. Conversion of 
tightly bound to covalently incorporated 2-azido- 
ANP moieties occurred with approx. 50% efficien- 
cy (50% acid-precipitable cpm). This high conver- 
sion efficiency is typical if protein concentrations 
are kept at 15 mg/ml during photolysis. The en- 
tire sample was injected into a Vydac C4 reversed- 
phase column and eluted by the same gradient 
described in section 2 for the CS column. The 
resulting A215nm and radioactivity profile are 
shown in fig. 1. Catalytic site-labeled peptide 
eluted at approx. 60 min or about 30% solvent B. 
The bottom panel of fig.1 also shows the 
radioactivity profile of similar tryptic peptides of 
EFi photolabeled by 2-azido-ANP bound at non- 
catalytic sites. Labeling and HPLC methods were 
identical to that described above except that the 
first incubation (15 min) contained 2-azido- 
p,y-32P]ATP (1.7 mM), and the second incuba- 
tion (5 min) contained ATP (15 mM) and MgCL 
(15 mM). Noncatalytic site-labeled peptide 
eluted at about 40 min or about 20% solvent B. 
Comparison of fig.1 catalytic site labeling with 
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Fig. 1. Reversed-phase HPLC separation of catalytic and 
noncatalytic site 2-azido-ANP-labeled tryptic peptides. 
The top panel shows the A215,,,,, trace of the catalytic site 
sample. The bottom panel shows the radioactivity 
profiles of both catalytic and noncatalytic site-labeled 
samples. 
noncatalytic site labeling demonstrates a clear 
distinction between the different labeled tryptic 
peptides. Both MFr and CFr tryptic peptides la- 
beled at noncatalytic or catalytic sites by 2-azido- 
ANP show similar HPLC elution patterns 
[14,17,18]. 
3.2. Purification of 2-azido-ANP-labeled non- 
catalytic and catalytic site peptides 
Fig.2 presents data from a 2-azido-ATP 
catalytic site-labeling experiment analogous to the 
experiment of fig.1 with the following modifica- 
tions. EFr (15 mg) was incubated for 10 min with 
1 mM ATP and passed through two consecutive 
Sephadex-centrifuge columns. 2-Azido-~,y-32P]- 
ATP (0.9 mM) was added and incubation con- 
tinued for 1 h. After a final Sephadex-centrifuge 
column, the sample was irradiated for 1 h and then 
acid precipitated. NHdHCO3 (1 ml at 0.1 M, ad- 
justed to pH 8 with 2 M NHdOH) and TPCK- 
trypsin (250 ,ug) were added and incubation at 
37°C was continued for 16 h. The sample was cen- 
trifuged (the pellet contained ~5% of total 
radioactivity) and the supernatant (18 nmol of 
labeled peptides) was separated by ion-exchange 
HPLC as described in section 2. Fig.2A shows the 
resulting A215 profile for the ion-exchange step. 
Fraction I, corresponding to the approximate elu- 
tion time of free ADP (about 28% solvent B), con- 
tained 12 nmol of labeled peptide. Fraction II, 
0-J _q---+;.o 
0 20 60 
minutes y 
AUFS=O 1 
B 13 04- h 
Fig.2. HPLC purification of labeled peptides. (A) 
HPLC anion-exchange separation of predominantly 
catalytic site-labeled tryptic peptides. (B) Reversed- 
phase HPLC separation of fraction I from panel A. 
Details are described in the text. 
corresponding to the approximate elution time of 
free ATP (about 82% solvent B), contained 
0.2 nmol of labeled peptide. No other fractions ex- 
cept the initial flow-through fraction contained 
significant amounts of radioactivity. 
Fig.2B shows the elution profile when 10 nmol 
of 32P-labeled peptides from fraction I above was 
applied to a CS reversed-phase column (described 
in section 2). Only peaks Ti, Tz, T3 and T4 (eluted 
between 25 and 29% solvent B) were radioactive 
and contained 0.5, 0.6, 3.5, and 2.2 nmol labeled 
peptide, respectively. The noncatalytic site pep- 
tides, Tr and Tz, correspond to 7 and 9%, while 
the catalytic site peptides T3 and T4 correspond to 
51 and 32% of the total radioactivity injected in 
this predominantly catalytic site-labeled EFr 
sample. 
In separate xperiments (not shown) where non- 
catalytic sites were predominantly photolabeled, 
peptides Ti and TZ were observed to be the major 
radioactive fractions while T3 and T4 were the 
minor radioactive components. Such experiments 
confirmed that peptides Tr and T2 were from non- 
catalytic sites and peptides T3 and T4 were from 
catalytic sites. The efficacy of the two step 
397 
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purification scheme outlined in section 2 is evident 
from comparison of fig.lA with fig.2B. The 
scheme may prove useful in purifying other 
phosphate-moiety derivatized peptides. 
Table 1 
Microsequence analyses of 2-azido-ANP modified 
peptides 
3.3. Analysis of catalytic and noncatalytic site 
Cycle PTH-amino acid residue (pmol) 
2-azido-ANP-labeled peptides 
Table 1 presents automated Edman gas-phase 
microsequencing data obtained from the non- 
catalytic site peptide, Tr. The sequence obtained 
can be aligned with the amino acid sequence 
deduced from the DNA sequence [ 191 starting with 
residue Gln-343 of the EFr P-subunit. No PTH 
derivative was detected at cycle 12, while all other 
cycles identified residues in complete agreement 
with the amino acid sequence in [ 191. The deduced 
amino acid sequence would have a tyrosyl residue 
at the corresponding cycle 12. As noted in [ 171, a 
PTH-derivatized tyrosine bearing an ADP moiety 
would have very limited solubility in the microse- 
quencer solvent system, precluding its detection. 
We conclude that the site of labeling on the EFr fl- 
subunit by 2-azido-ANP when bound at non- 
catalytic sites is Tyr-354. 
Noncatalytic peptide, Catalytic peptide, 
Tr T3 
Table 1 also presents the microsequencing data 
for the catalytic site peptide, T3. This sequence can 
be aligned with the deduced amino acid sequence 
in [19] starting with residue Gln-329 of the EFr ,&- 
subunit. No PTH derivative was detected in cycle 
8. By analogy to the reasoning given above, we 
conclude that cycle 8 corresponds to the modified 
P-subunit residue, Tyr-33 1. 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
Gln (39) 
Leu (26) 
Asp (33) 
Pro (28) 
Leu (17) 
Val (17) 
Val (25) 
GlY (11) 
Gin (10) 
Glu (7) 
His (5) 
_ 
Asp (4) 
Thr (3) 
Ala (5) 
Arg (1) 
Gin (65) 
Ile (38) 
Ala (48) 
Ser (15) 
Leu (30) 
Gly (29) 
Ile (24) 
- 
Pro (31) 
Ala (22) 
Val (14) 
Asp (22) 
Pro (16) 
Leu (9) 
Asp (10) 
Ser (2) 
Thr (2) 
Ser (1) 
Arg (1) 
160 pmol of peptide Ti and 260 pmol of peptide T3 were 
analyzed in these experiments. The dashes indicate that 
no quantifiable PTH derivative was present 
Peptides T2 and T4 were resistant to Edman moiety due to its greater anionic character. In 
degradation as no detectable PTH derivatives were other experiments, EFr was labeled with 2-azido- 
observed in any of the automated cycles (replicate ANP and the &subunits were dissociated and 
samples of up to 0.5 nmol each of the radiolabeled isolated. After the isolated &subunits were sub- 
peptides). Comparison of the amino acid composi- jected to proteolysis, purification and sequencing 
tions (acid hydrolysis) of the four labeled peptides of the labeled peptides resulted in identification of 
suggests that T2 is identical to the noncatalytic site catalytic and noncatalytic site peptides identical to 
peptide Tr, and that T4 is identical to the catalytic those of fig.2 and tables 1 and 2 (not shown). As 
site peptide T3 (table 2). The differences in HPLC with CFr [14], only ADP-derivatized peptides were 
elution time and susceptibility to Edman degrada- found with catalytic-site labeling, and both ADP- 
tion may reflect cyclization of the N-terminal and ATP-derivatized peptides were found with 
glutamine residues of peptides TZ and T4. noncatalytic-site labeling. 
Fraction II of fig.2A has been purified on 
reversed-phase HPLC and sequenced and been 
found to be identical to the noncatalytic site pep- 
tide, Tr (not shown). We surmise that the cycle 12, 
Tyr-354 of this sample has been modified with a 
2-azido-ATP moiety rather than a 2-azido-ADP 
It is important to mention that between 5 and 
10% of the 2-azido-ANP covalently incorporated 
into EFr modifies the a-subunit as determined by 
SDS-polyacrylamide gel electrophoresis and 
autoradiography (not shown). We are currently 
working to identify the labeled cY-peptide( 
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Table 2 
Amino acid compositions of 2-azido-ANP-modified peptides 
Noncatalytic site peptides Catalytic site peptides 
Residue TI T2 Residue I-3 T4 
(mol/mol) (mol/mol) (mol/mol) (mol/mol) 
D (2) 1.7 1.6 D (2) 1.4 1.5. 
E (3) 2.0 2.3 E (1) 1.1 1.2 
g (0) 0.7 0.5 8 (3) 2.1 1.9 
C (I) 1.7 1.2 C (1) 1.1 1.2 
I-I (1) 0.8 0.7 f-T (0) co.1 0.2 
R (1) 1.0 1.0 R (1) 1.0 1.0 
T (1) 0.8 0.9 T (1) 0.9 0.9 
A (1) 0.8 1.0 A (2) 1.5 1.4 
P (1) 1.0 1.1 P (2) 1.7 1.8 
y (1) 0.2 0.3 y (1) 0.3 <O.l 
V (2) 1.2 1.7 V (1) 1.5 1.1 
M (0) <O.l 0.3 M (0) <O.l 0.1 
1 (0) 0.3 0.2 1 (2) 1.2 1.3 
L (2) 1.2 1.4 L (2) 1.4 1.5 
F (0) 0.2 0.1 F (0) <O.l 0.2 
R (0) 0.3 0.3 R (0) <O.l 0.3 
D and E represent D + N and E + Q, respectively. W and C were not determined. 
Numbers in parentheses represent he values from the sequence determinations of 
peptides TI and T3, respectively. Between 0.25 and 0.50 nmol of each peptide was 
subjected to analysis 
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4. DISCUSSION 
It has been recognized that the major subunits of 
Fr-ATPases from mitochondria, chloroplasts and 
bacteria are similar. Indeed, in view of recent 
reports of the amino acid sequences of the cy- and 
P-subunits of MFr, CFr and EFr (see [19]), it is ap- 
parent that these proteins from very disparate 
species are highly conserved. One might predict 
that each of the three enzymes may be quite similar 
in the basic structures of the Fi sector. Until 
recently, CFr was widely regarded as having only 
three nucleotide binding sites, leaving a ,discrepan- 
cy in observed structure when contrasted against 
the six sites observed in MFi and EFi [5,6]. Xue et 
al. [18], in confirmation and extension of sugges- 
tions of others, report strong evidence that CFi, 
like MFr and EFr, probably has a total of six 
nucleotide binding sites, comprised of catalytic 
and noncatalytic sites. 
Fig.3 summarizes 2-azido-ANP labeling data 
from experiments on MFi [17,20], CFi [14], and 
EFr (this report). It is apparent from the figure 
that 2-azido-ANP modifies highly conserved ,B- 
subunit peptides at homologous tyrosyl residues 
when either catalytic or noncatalytic sites are filled 
with 2-azido-ANP. The direct demonstration of 
similar catalytic and noncatalytic peptides 
modified by 2-azido-ANP in MFi, CFr and EFi 
strongly supports the structural and functional 
analogies between the three enzymes. The ability to 
directly distinguish between catalytic and non- 
catalytic nucleotide binding, and between incor- 
porated ADP- and ATP-moieties, should serve to 
advance efforts at understanding the effects of 
bound nucleotides on the function of the ATP 
synthase. 
When nucleotide sites on EFi are modified by 
2-azido-ANP moieties, small amounts of the 
covalently incorporated analog are found on the a- 
subunit. The majority of analog incorporated into 
EFr reacts with the &subunit presumably because 
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F1 Source Modified Residue* Labeled Peptide 
Bovine 
Mitochondria 
Spinach 
Chloroplast 
Escherichia 
coli 
Tyr-34sarb 
Tyr-362= 
Tyr-331d 
GIY*PAVDPLDS 
2-AZIDO-ANP-LABELED NONCATALYTIC P-SUBUNIT PEPTIDES 
Fl Source Modified Residue* Labeled Peptide 
Bovine 
Mitochondria Tyr-36Sb 
Spinach 
Chloroplast Tyr-385C R 
Escherichia 
coli Tyr-354d 
Fig.3. Catalytic and noncatalytic site tryptic peptides of MFr, CF, and EF1 labeled with 2-azido-ANP moieties. (*) 
Residue number refers to the site of 2-azido-ANP modification counted from the N-terminus of the respective ,&- 
subunit. Boxes indicate identically conserved residues of the relevant regions of the&subunits from ten different species 
[19]. a From [20]; b from [17]; ’ from [14]; d from this work. 
the 2-position of the enzyme bound 2-azido-ANP 
exists in an orientation closest to the &subunit. 
The possibility that catalytic and/or noncatalytic 
binding sites may be formed at the interfaces of the 
cr- and &subunits should not be discounted. 
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